NervGen (NGEN) Stock Price Target Cut to $15 Due to Dilution
Published on 7/14/2026
AI Summary
Summarized by AI from the source belowH.C. Wainwright has reduced the stock price target for NervGen Pharma (NGEN) to $15. This adjustment reflects concerns over share dilution affecting the company's market valuation. Investors may perceive this downward revision as a sign of potential challenges for NervGen in maintaining stock price stability. The decrease in the target price could impact investor confidence and trading volumes going forward.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
Related News
Markets
Investing $30,000 in 3 TSX Stocks Generates Over $1,400 Annual Income
Aug 28
Markets
Core Scientific options activity signals potential major move
Aug 28
Markets
Federal Reserve Interest Hike Odds Rise to 60% After Warsh Speech
Aug 28
Markets
Fidelity & Guaranty Life sells $628,590 in Crescent Capital BDC shares
Aug 28